Literature DB >> 1425958

JMV 449: a pseudopeptide analogue of neurotensin-(8-13) with highly potent and long-lasting hypothermic and analgesic effects in the mouse.

I Dubuc1, J Costentin, S Doulut, M Rodriguez, J Martinez, P Kitabgi.   

Abstract

We recently reported that H-Lys psi (CH2NH)Lys-Pro-Tyr-Ile-Leu-OH (JMV 449), a pseudopeptide analogue of neurotensin-(8-13) with a reduced CH2NH bond in position 8-9, was about 3 times more potent than neurotensin in binding to mouse brain membranes and in contracting the guinea-pig ileum, and was markedly more resistant to degradation than neurotensin when exposed to rat brain membranes. In the present study, we compared the time courses and dose-response relationships for the ability of i.c.v. injected neurotensin and JMV 449 to elicit hypothermia and analgesia (tail-flick test) in the mouse. The results show that the pseudopeptide analogue behaved as a highly potent and long-lasting neurotensin agonist in these two in vivo bioassays. The analogue should prove very useful for studying the effects of chronic neurotensin receptor stimulation in vitro and in vivo.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1425958     DOI: 10.1016/0014-2999(92)90314-t

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

Review 1.  Neurotensin agonists: potential in the treatment of schizophrenia.

Authors:  Mona Boules; Amanda Shaw; Paul Fredrickson; Elliott Richelson
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

2.  NT79: A novel neurotensin analog with selective behavioral effects.

Authors:  Mona Boules; Yanqi Liang; Siobhan Briody; Tomofumi Miura; Irfan Fauq; Alfredo Oliveros; Mina Wilson; Shaheen Khaniyev; Katrina Williams; Zhimin Li; Yanfei Qi; Michael Katovich; Elliott Richelson
Journal:  Brain Res       Date:  2009-10-27       Impact factor: 3.252

3.  Acute and delayed protective effects of pharmacologically induced hypothermia in an intracerebral hemorrhage stroke model of mice.

Authors:  S Wei; J Sun; J Li; L Wang; C L Hall; T A Dix; O Mohamad; L Wei; S P Yu
Journal:  Neuroscience       Date:  2013-07-30       Impact factor: 3.590

4.  Neurotensin as a source of cyclic AMP and co-mitogen in fibrolamellar hepatocellular carcinoma.

Authors:  Kimberly J Riehle; Heidi L Kenerson; Kevin M Riggle; Rigney Turnham; Kevin Sullivan; Renay Bauer; John D Scott; Raymond S Yeung
Journal:  Oncotarget       Date:  2019-08-20

5.  Optimized Opioid-Neurotensin Multitarget Peptides: From Design to Structure-Activity Relationship Studies.

Authors:  Simon Gonzalez; Maria Dumitrascuta; Emilie Eiselt; Stevany Louis; Linda Kunze; Annalisa Blasiol; Mélanie Vivancos; Santo Previti; Elke Dewolf; Charlotte Martin; Dirk Tourwé; Florine Cavelier; Louis Gendron; Philippe Sarret; Mariana Spetea; Steven Ballet
Journal:  J Med Chem       Date:  2020-09-23       Impact factor: 7.446

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.